BUZZ-Terns Pharma rises on early data for blood cancer drug

Reuters
2024-12-03

** Shares of Terns Pharmaceuticals rise ~6% to $6.5 premarket

** Co says its experimental drug to treat a type of blood cancer showed clinically meaningful responses in patients at two lowest dose levels

** The drug, TERN-701, showed no dose-limiting toxicities across three completed dose levels, and no side-effect-related dose reductions or discontinuations - TERN

** TERN plans to share additional safety and efficacy data in late 2025

** The initial data was above expectations and supported long-term use, according to BMO Capital analysts

** TERN-701 is being developed to treat heavily pre-treated patients with relapsed/refractory chronic myeloid leukemia

** Up to last close, shares down ~5% YTD

(Reporting by Mariam Sunny in Bengaluru)

((Mariam.ESunny@thomsonreuters.com;))

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10